About 2.2% of the global population meets the clinical criteria for a substance use disorder, a figure that covers both alcohol and illicit drugs combined. That translates to roughly one in every 45 people worldwide. But that single number hides enormous variation depending on which substances you count, how “addiction” is defined, and which populations you look at. Include tobacco dependence and the figure multiplies several times over. Strip out alcohol and focus only on drugs like opioids, cannabis, and cocaine, and the rate drops to about 0.8%.
What That 2.2% Actually Measures
The most widely cited global estimates come from the Global Burden of Disease project, which tallies cases using diagnostic criteria from frameworks like the DSM and ICD classification systems. A worldwide analysis of mental and substance use disorders placed the overall prevalence of substance use disorders at 2.2%, with alcohol use disorders accounting for roughly 1.5% and all other drug use disorders together making up the remaining 0.8%.1PubMed. Analysis of global prevalence of mental and substance use disorders within countries: focus on sociodemographic characteristics and income levels Within that 0.8%, cannabis disorders were the most common (about 0.32%), followed by opioids (0.29%), amphetamines (0.10%), and cocaine (0.06%).
These numbers capture people whose drug use has crossed a clinical threshold, meaning it causes significant distress, impaired functioning, or both. They do not count everyone who uses drugs recreationally or even regularly. A person who drinks heavily on weekends but whose life is otherwise unaffected might not qualify, while someone whose opioid use has derailed their work and relationships would. The diagnostic systems that produce these estimates, the DSM and the ICD, draw the line somewhat differently. The DSM groups all problematic use along a single spectrum of severity, while the ICD retains a sharper distinction between dependence and harmful use.2PubMed. Substance use and addictive disorders in DSM-5 and ICD 10 and the draft ICD 11 Field trials have shown that the DSM tends to yield somewhat higher prevalence rates than the ICD for the same population, partly because its broader definition catches milder cases.3PubMed. Cross system agreement for substance use disorders: DSM-III-R, DSM-IV and ICD-10
This matters because when you see a headline claiming some percentage of the world is addicted to drugs, the number depends on which diagnostic system generated it and whether alcohol and tobacco are folded in. The 2.2% figure is a reasonable middle ground for alcohol plus illicit drugs, but it is not the whole story.
How the Numbers Break Down by Substance
Alcohol dominates the global picture of substance use disorders. A systematic analysis covering 195 countries estimated about 100 million cases of alcohol use disorders in 2016, making it the single most common form of substance addiction worldwide.4The Lancet. The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990–2016 By 2021, about 56 million new alcohol use disorder cases were recorded in a single year.5PubMed Central. Global burden and trend of substance use disorders, self-harm, and interpersonal violence from 1990 to 2021, with projection to 2040
For illicit drugs specifically, the 2021 data from the Global Burden of Disease Study counted about 13.6 million new cases of drug use disorders that year, along with roughly 137,000 deaths.6PubMed Central. Global burden of disease due to opioid, amphetamine, cocaine, and cannabis use disorders, 1990-2021 Cannabis use disorder produced the largest number of new cases, around 3.6 million, reflecting the drug’s widespread availability and use globally.6PubMed Central. Global burden of disease due to opioid, amphetamine, cocaine, and cannabis use disorders, 1990-2021 But opioid use disorder was far deadlier, responsible for roughly 100,000 of those 137,000 deaths and carrying the highest burden of disability-adjusted life years lost.6PubMed Central. Global burden of disease due to opioid, amphetamine, cocaine, and cannabis use disorders, 1990-2021 In other words, cannabis addiction is more common, but opioid addiction is far more dangerous.
The gap between the two tells you something important about how “burden” differs from “prevalence.” A substance can have a relatively low addiction rate but an outsized impact on death and disability, which is precisely the case with opioids. Amphetamine and cocaine use disorders are less prevalent than either cannabis or opioids, but they too contribute meaningfully to global health loss, especially in regions where synthetic stimulants have flooded the market in recent years.
The Tobacco Question
Most global addiction statistics leave out tobacco, which is arguably the biggest oversight. About 1.18 billion people worldwide regularly smoke, with prevalence around 33% among men and about 7% among women.7PubMed Central. Evolution of the global smoking epidemic over the past half century: strengthening the evidence base for policy action Nicotine dependence meets every clinical criterion for addiction, yet because tobacco is legal and widely sold, it is often reported separately from “drug addiction” statistics. An estimated 7 million deaths in 2020 were attributable to smoking.7PubMed Central. Evolution of the global smoking epidemic over the past half century: strengthening the evidence base for policy action
If you folded nicotine dependence into the global addiction figure, the percentage of the world living with some form of substance addiction would jump dramatically, well beyond the 2.2% cited for alcohol and illicit drugs. The reason tobacco is typically excluded is partly historical, partly institutional: the public health response to tobacco has been channeled through its own frameworks, legislation, and funding streams, separate from the “drug policy” world. But from a neurobiological standpoint, nicotine hooks the brain through the same dopamine reward circuits as heroin or cocaine.8PubMed Central. The Neuroscience of Drug Reward and Addiction
Who Is Most Affected
Substance use disorders are not evenly distributed across the population. Age is one of the strongest predictors. Rates peak sharply in the early twenties and decline steadily from there.9PubMed Central. Global burden of substance use disorders in adolescents and young adults aged 10–24 years from 1990 to 2021 In the United States, alcohol use disorder prevalence hit about 32% among men at age 25 and 24% among women around age 22, then dropped steadily with age. Cannabis use disorder was highest at age 18, around 13% for men and 7% for women, and fell steeply by age 30.10PubMed Central. Age trends in rates of substance use disorders across ages 18–90: Differences by gender and race/ethnicity One interesting wrinkle: opioid use disorder showed a crossover pattern where men had higher rates in young adulthood but women overtook them in older age, roughly around the late sixties and seventies.10PubMed Central. Age trends in rates of substance use disorders across ages 18–90: Differences by gender and race/ethnicity
Gender differences are consistent across most substances. Men have higher odds of accessing, trying, and developing a disorder for cannabis, cocaine, and most other illicit drugs compared to women. Research based on a large U.S. national survey found that the gender gap starts at the point of access and widens at each stage, with the biggest gap at the jump from having access to actually trying the drug.11PubMed Central. Gender differences in illicit drug access, use and use disorder: Analysis of National Survey on Drug Use and Health data This doesn’t mean women are immune; it means that social norms, opportunity, and possibly biological factors all stack the probabilities differently.
Income and socioeconomic status add another layer. Among Americans who had ever used illicit drugs, those in the lowest income bracket were about 36% more likely to report substance-abuse-related problems than those in the highest bracket, after adjusting for age, race, marital status, and education.12PubMed Central. Socioeconomic Disparities and Self-reported Substance Abuse-related Problems Lower income does not cause addiction on its own, but the stresses that come with poverty, fewer treatment options, and less social support all make it harder to avoid or recover from problematic use.
Genetics and Individual Vulnerability
Not everyone who tries an addictive substance develops a disorder, and genetics explains a meaningful share of why. Twin studies consistently estimate that somewhere between 30% and 70% of the variation in addiction risk is heritable, depending on the substance.13PubMed. Are there genetic influences on addiction: evidence from family, adoption and twin studies Cocaine dependence sits near the top of that range, with heritability estimates as high as 72%, while hallucinogen-related disorders are closer to the bottom at around 39%.14PubMed Central. The genetic basis of addictive disorders For nicotine, the estimate runs roughly 33% to 71%; for alcohol, 48% to 66%; for cannabis, 51% to 59%.15Translational Psychiatry. The genetics of addiction—a translational perspective
These numbers do not mean there is a single “addiction gene.” Hundreds of genetic variants each nudge risk up or down by small amounts, and they interact with environmental factors at every stage. Genes influence who is likely to try a substance, who finds the experience rewarding enough to repeat, and who loses the ability to moderate their use. The neurobiology follows a consistent pattern across substances: the reinforcing effects of drugs depend heavily on dopamine signaling in a brain region called the nucleus accumbens, and chronic exposure triggers changes in communication between the brain’s reward, decision-making, and memory systems that can lock in compulsive use.8PubMed Central. The Neuroscience of Drug Reward and Addiction
The Trend Is Getting Worse, Not Better
Global drug addiction numbers have been climbing for decades. The total number of deaths attributed to drug use disorders rose by about 122% between 1990 and 2021, reaching roughly 137,000 deaths per year. The age-standardized mortality rate increased from about 1.3 to 1.7 per 100,000.16PubMed Central. Global burden on drug use disorders from 1990 to 2021 and projections to 2046 The total burden of disability-adjusted life years, a measure combining years lost to premature death and years lived with disability, climbed by about 75% over the same period.16PubMed Central. Global burden on drug use disorders from 1990 to 2021 and projections to 2046
What makes this pattern especially troubling is that it is concentrated. The burden falls disproportionately on young people, men, and wealthier nations. Drug use accounted for about 1.3% of all disability-adjusted life years globally in 2016, which sounds small until you realize that translates to roughly 32 million life years lost in a single year.4The Lancet. The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990–2016 Opioids drive the lion’s share of this increase, particularly in North America, where the synthetic opioid crisis has pushed overdose deaths to historic levels.
Prescription drugs have also reshaped the landscape. A United Nations panel warned years ago that the abuse of prescription medications containing narcotics or psychotropic drugs was on track to exceed illicit drug use worldwide, a prediction that has played out in several high-income countries.17JAMA. Prescription Drug Abuse Rises Globally The boundaries between licit and illicit drug markets have blurred as diverted prescriptions, counterfeit pills, and online pharmacies feed demand.
Why the Real Number Is Almost Certainly Higher
Global estimates rely heavily on surveys and health-system data, both of which undercount addiction. People underreport drug use on surveys due to stigma, fear of legal consequences, and simple forgetfulness. In many low-income countries, there is no meaningful surveillance infrastructure for substance use disorders at all; the data is either extrapolated from neighboring countries or based on expert estimates rather than actual measurement.
Stigma is the bigger driver of undercounting in countries that do have surveys. Admitting to illegal drug use on a questionnaire, even an anonymous one, is something many people avoid. Certain populations, including people who are homeless, incarcerated, or living in conflict zones, are systematically excluded from household surveys, and these groups have some of the highest rates of substance use disorders. The 2.2% figure is a floor, not a ceiling. The true global prevalence is likely higher, though by how much is genuinely unknown.
The Treatment Gap
Even at the lower-bound estimates, the global response to drug addiction falls far short. A systematic review of harm reduction and treatment coverage for people who inject drugs found that most countries are failing to meet even moderate targets set by international health agencies. Only five countries, collectively home to about 2% of the world’s injecting drug users, were providing high coverage of both needle and syringe programs and opioid agonist therapy.18The Lancet Global Health. Global coverage of interventions to prevent and manage drug-related harms among people who inject drugs: a systematic review That means the overwhelming majority of people who inject drugs worldwide lack access to the interventions most proven to reduce death, disease, and ongoing addiction.
For opioid use disorder specifically, evidence supports opioid agonist treatment, medications like methadone and buprenorphine, as effective at retaining people in care and reducing illicit use. Even interim programs that provide medication while people wait for a full treatment slot outperform being on a waiting list with no medication at all.19PubMed Central. Interim opioid agonist treatment for opioid addiction: a systematic review Yet in most of the world, these treatments remain unavailable, underfunded, or heavily restricted by law.
The Economic Toll
Addiction does not just damage health; it drains economies. In the United States alone, productivity losses attributable to substance use disorders were estimated at about $93 billion in 2023. The largest chunk came from people being unable to work at all, accounting for roughly $45 billion, followed by absenteeism at around $26 billion and reduced productivity while at work at about $12 billion.20PubMed Central. Productivity Losses From Substance Use Disorder in the U.S. in 2023 Those figures cover only lost work output, not healthcare costs, criminal justice spending, or the harder-to-quantify costs borne by families and communities.
No comparable single estimate exists for the entire world, but given that the U.S. accounts for a large but not dominant share of global drug use disorders, the worldwide economic cost is almost certainly many times higher. Countries with weaker healthcare systems and social safety nets may see smaller absolute dollar figures but proportionally larger disruptions to their economies and human capital.
Mental Health and Addiction Overlap
A recurring finding across addiction research is how frequently substance use disorders occur alongside other mental health conditions. Depression, anxiety disorders, post-traumatic stress, and personality disorders all show elevated rates among people with addiction, and the relationship runs in both directions: mental illness increases the risk of developing a substance use disorder, and substance use worsens mental health outcomes. The research literature uses the term “dual diagnosis” so frequently that it has become one of the most common keywords in the field, reflecting how central this overlap is to understanding and treating addiction.21PubMed Central. Research landscape analysis on dual diagnosis of substance use and mental health disorders: key contributors, research hotspots, and emerging research topics
This comorbidity complicates both measurement and treatment. Someone whose heavy drinking is driven by untreated PTSD may not respond to addiction treatment that ignores the underlying trauma. Someone whose depression is worsened by stimulant withdrawal may cycle between psychiatric care and addiction services without either system addressing the full picture. Integrated treatment, care that tackles both problems simultaneously, consistently produces better outcomes than treating each condition in isolation, yet health systems in most countries still separate mental health services from addiction services, forcing patients to navigate two bureaucracies when they can barely manage one.